Phase Ia/b study of DSB2455, a PARP1 inhibitor in advanced malignancies

This Phase Ia/b open-label adaptive trial evaluates the safety, tolerability, and activity of DSB2455, a small molecule PARP1 selective inhibitor, as monotherapy in participants with advanced or metastatic breast, prostate, or ovarian cancer. The design includes dose escalation followed by expansion cohorts, with Duke Street Bio Ltd as the sponsor, to assess its novel therapeutic potential. Though not specified, this trial likely makes sense for HRD+ genetic alterations in these cancer types.